Breaking news

BETA-BET: Pioneering Gene-Editing Initiative Targets Thalassemia’s Genetic Core

by THEFUTURE.TEAM

Introduction

A groundbreaking project at the Cyprus Institute of Neurology and Genetics (CING) is set to transform the treatment landscape for beta-thalassemia, the most common inherited blood disorder in Cyprus. The initiative aims to deliver a one-time, curative therapy by leveraging advanced gene-editing technologies.

Path to Breakthrough

The Molecular Genetics Thalassaemia Department (MGTD) has announced the launch of the BETA-BET: Targeted Base Editing for Beta Thalassemia project. This ambitious program focuses on addressing the HBBIVSI-110 mutation, the primary genetic culprit behind the condition on the island. Beta-thalassemia arises from abnormalities in the β-globin gene (HBB), which plays a vital role in oxygen transportation through haemoglobin. Traditionally, patients have depended on lifelong blood transfusions to manage chronic anemia, a burden that this new therapy seeks to eliminate.

Expanding the Scope of Base Editing

The BETA-BET project, funded with a substantial budget of €198.83 million by the Research and Innovation Foundation (RIF) along with co-funding from the European Union and the Republic of Cyprus, pioneers the use of “base editing” technology. This method, comparable to a precise biological pencil and eraser, corrects single “letter” errors in the DNA sequence without inducing double-stranded breaks. An earlier preclinical study—conducted in collaboration with leading institutions across Greece and Germany—demonstrated the potential of these tools to effectively restore the production of functional red blood cells in individuals homozygous for the HBBIVSI-110 mutation.

Innovative Delivery System

Beyond expanding the patient group to include compound heterozygotes, whose prevalence significantly exceeds that of homozygotes in many regions, the project introduces a revolutionary delivery mechanism. Engineered virus-like particles (eVLPs) are being developed to function as microscopic delivery drones, transporting gene-editing complexes directly to blood-forming stem cells. This strategy could simplify treatment administration to a single injection, thereby eliminating the current, complicated process of ex vivo stem cell manipulation.

Collaborative Leadership and Global Partnerships

Under the expert guidance of Dr Petros Patsali, Associate Scientist at MGTD, and a team of renowned researchers, the project draws on a network of national and international partners. Esteemed collaborators include institutions such as George Papanikolaou Hospital, the Aristotle University of Thessaloniki, and the University of Freiburg, among others. These partnerships not only bolster the project’s scientific rigor but also enhance its global relevance, particularly in high-incidence areas like Greece and Egypt.

Conclusion

By extending the precision of base editing to a wider patient demographic and integrating novel delivery systems, the BETA-BET initiative represents a significant advance in gene therapy. This innovative approach could eventually provide a transformative, one-time treatment for thousands of patients, marking a milestone in the pursuit of a definitive cure for thalassemia.

Mercedes-Benz Posts Higher Profit Despite China Slowdown

by THEFUTURE.TEAM

Mercedes-Benz reported stronger-than-expected second-quarter results, lifting its shares on Tuesday despite mounting pressure from Chinese automakers and a weaker outlook for sales and revenue.

The earnings provided a boost for Europe’s auto sector, where manufacturers continue to grapple with tariffs, softer demand and intensifying competition from Chinese rivals. Volkswagen, Mercedes-Benz and BMW have all accelerated restructuring efforts in response.

Cost Discipline Lifts Quarterly Profit

Mercedes-Benz shares rose as much as 5.9% following the results before trimming gains to trade 3.5% higher by 1118 GMT. The company reaffirmed its profit margin guidance for its core passenger car business after reporting an adjusted return on sales of 4.0% for the second quarter, above market expectations and within its 3% to 5% target range.

“In an environment where some automakers are ringing alarm bells on their competitive positioning, Mercedes delivered a clear and confident message,” Morningstar analyst Rella Suskin said.

Second-quarter operating profit increased 22% to €1.5 billion ($1.7 billion), despite a 3% decline in revenue. Lower administrative and research and development costs, together with strong performances from the financial services and vans divisions, supported earnings, while the results also included a €131 million gain related to the planned sale of leasing subsidiary Athlon.

China Remains The Key Pressure Point

Despite stronger profitability, Mercedes continues to face a challenging market environment. Sales in China fell 30% during the second quarter, prompting the company to abandon earlier expectations for stable car sales and group revenue. It now expects both to decline slightly from a year earlier.

BMW also lowered its outlook in June following a deeper-than-expected slowdown in China, highlighting the pressure facing Germany’s premium carmakers. At the same time, Mercedes said Chinese manufacturers are increasingly expanding into European markets, although Chief Executive Ola Kaellenius said their focus remains on higher-volume segments rather than the premium market.

“But that is not a reason to sit back and be relaxed,” he said.

Manufacturing Shift Continues

Mercedes is also reshaping its manufacturing footprint. The company said its German factories will undergo a more aggressive push toward leaner production, although it declined to provide further details while talks with labour representatives continue. Production is also being expanded in lower-cost Eastern European locations, including Hungary, where the company is increasing capacity at its Kecskemet plant, as well as in Poland.

Chief Financial Officer Harald Wilhelm said the full-year margin for the passenger car division is expected to come in at the lower end of the company’s guidance range, reflecting a higher share of electric vehicle sales in Europe, which remain more expensive to produce and continue to weigh on profitability.

“We must continue to work flat out to reduce costs so that we can remain competitive on the prices of our products,” Kaellenius said.

Aretilaw firm
Uol
eCredo
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter